Core Viewpoint - QianYuan Pharmaceutical (300254.SZ) announced that its major shareholder, Zhao Qun, increased his stake in the company, becoming the largest single shareholder with 6.36% of the total share capital [1] Shareholding Changes - Zhao Qun acquired an additional 15,781,792 shares through the Shenzhen Stock Exchange from September 11 to September 12, 2025 [1] - Zhao Qun's action partner, Huang Lequn, holds 5,465,060 shares, representing 2.20% of the total share capital [1] - Together, Zhao Qun and Huang Lequn own a total of 21,246,852 shares, accounting for 8.56% of the total share capital [1] Shareholder Structure - The change in the largest single shareholder does not affect the company's compliance with listing conditions [1] - Zhao Qun and Huang Lequn remain the largest shareholders, and the company does not have a controlling shareholder or actual controller [1]

证券代码：300254 证券简称：仟源医药 公告编号：2025-062 山西仟源医药集团股份有限公司 关于持股5%以上股东增持公司股份的比例触及1%的整数倍 暨公司单一第一大股东变更的公告 公司持股 5%以上股东、董事、总裁赵群先生保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示：持股5%以上股东、董事、总裁赵群先生于2025年9月11日-2025 年9月12日通过深圳证券交易所证券交易系统以集中竞价交易方式增持了公司股 份，增持完成后，持有公司股份15,781,792股，占公司总股本的6.36%，成为公 司单一第一大股东。同时，赵群先生的一致行动人黄乐群先生持股5,465,060股， 占公司总股本的2.20%，赵群先生及其一致行动人黄乐群先生合计持股21,246,852 股，占公司总股本的8.56%。本次单一第一大股东变更不会导致公司股权分布不 符合上市条件，公司第一大股东仍为赵群先生及其一致行动人黄乐群先生，公司 仍无实际控制人和控股股东，不会导致公司实际控制人及控 ...

Core Viewpoint - On September 7, Suzhou Bank disclosed plans for share buybacks by its directors and senior management, while 20 A-share listed companies announced share reductions by their executives and shareholders [1][2]. Group 1: Share Buybacks - Suzhou Bank's directors, supervisors, and senior management plan to buy back shares worth no less than 4.2 million yuan [2]. Group 2: Share Reductions - Multiple directors and executives from Zhuhai Co. plan to reduce their shareholdings [2]. - Specific shareholders of Yingyang Intelligent, including directors, plan to reduce their stakes [2]. - Nantong Yuxiang intends to reduce its holdings by up to 0.66% in Hongde Co. [2]. - Shareholders of Xiangshan Co. plan to reduce their holdings by no more than 3% [2]. - Five directors and executives of Qianyuan Pharmaceutical plan to reduce their holdings by up to 0.1718% [2]. - Controlling shareholders and executives of Xingshuai Co. plan to reduce their holdings by no more than 2.71% [2]. - Vice President Liu Bin of Rongke Technology plans to reduce his holdings by no more than 63,000 shares [2]. - Shareholder Lei Yan Investment of Green Alliance Technology plans to reduce its holdings by no more than 1.63% [2]. - Controlling shareholders and actual controllers of Runhe Materials plan to reduce their holdings by no more than 3% [2]. - Sunshine Life intends to reduce its holdings in Huakang Clean by no more than 3% [2]. - Shareholder Ruan Jilin of Baida Precision plans to reduce his holdings by no more than 0.99% [2]. - Controlling shareholders and actual controllers of Jusa Long plan to reduce their holdings by no more than 3% [2]. - Controlling shareholder Yulide Group of Youlide plans to reduce its holdings by no more than 2% [2]. - Shareholders of Lutianhua plan to collectively reduce their holdings by no more than 3% [2]. - Dazhi Yintai intends to reduce its holdings in Wushang Group by no more than 22.4971 million shares [2]. - Shareholder Shunfeng Investment of Kejie Intelligent plans to reduce its holdings by no more than 3% [2]. - Shareholders of Shangwei Co. plan to reduce their holdings by no more than 3% [2]. - Jiangshan Co. intends to reduce its holdings by no more than 3% [2]. - Water Planning Investment plans to reduce its holdings in Deepwater Planning by no more than 3% [2]. - Controlling shareholder and actual controller Xie Qian of Zhuoyi Information plans to reduce his holdings by no more than 3% [2].

Group 1 - QianYuan Pharmaceutical announced that several executives plan to reduce their holdings in the company by a total of approximately 290,000 shares, which represents 0.1165% of the total share capital [1] - The company's revenue composition for the year 2024 is as follows: pharmaceutical manufacturing accounts for 96.68%, DNA gene preservation and prenatal environment testing services account for 1.93%, health food accounts for 0.79%, other businesses account for 0.51%, and commercial activities account for 0.1% [1] - As of the report, QianYuan Pharmaceutical has a market capitalization of 2.7 billion yuan [2]

Group 1 - The company Shanxi Qianyuan Pharmaceutical Group Co., Ltd. announced a pre-disclosure of share reduction by several directors and senior management [1] - The total shares planned to be reduced by the five individuals amount to no more than 426,600 shares, representing 0.1718% of the company's total share capital [1] - The individuals involved in the reduction include Yu Junxian, Gu Baoping, Yu Yingmin, He Yanjie, and Luo Kairui, with specific shareholdings and planned reductions detailed [1][2] Group 2 - The reasons for the share reduction include tax payments related to equity incentives and personal funding needs [2] - The shares to be reduced are sourced from various holdings, including pre-IPO shares, capital reserve conversions, and equity incentive grants [2] - The reduction price will be determined based on market conditions at the time of the sale, indicating some uncertainty in the execution of the plan [3] Group 3 - The share reduction plan does not violate any relevant laws or regulations and will not lead to changes in the company's control or governance structure [3] - The company will continue to monitor the progress of the share reduction plan and fulfill its information disclosure obligations as required [3]

Core Viewpoint - QianYuan Pharmaceutical (300254.SZ) announced that several executives plan to reduce their holdings in the company within three months after a 15 trading day period from the announcement date [1] Summary by Relevant Categories Shareholding Reduction - Executive Yu Junxian plans to reduce holdings by up to 289,200 shares, accounting for 0.1165% of the total share capital of the company [1] - Executive Gu Baoping plans to reduce holdings by up to 43,700 shares, accounting for 0.0176% of the total share capital of the company [1] - Executive Yu Yingmin plans to reduce holdings by up to 43,700 shares, accounting for 0.0176% of the total share capital of the company [1] - Executive He Yanjie plans to reduce holdings by up to 25,000 shares, accounting for 0.0101% of the total share capital of the company [1] - Executive Luo Kairui plans to reduce holdings by up to 25,000 shares, accounting for 0.0101% of the total share capital of the company [1]

证券代码：300254 证券简称：仟源医药 公告编号：2025-061 山西仟源医药集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 分别持有本公司股份 1,336,800 股(占公司总股本 0.5383%)、325,173 股（占 公司总股本 0.1309%）、325,173 股（占公司总股本 0.1309%）、250,000 股（占公 司总股本 0.1007%）、250,000 股（占公司总股本 0.1007%）的董事、高级管理人 员俞俊贤先生、高级管理人员顾宝平先生、虞英民先生、贺延捷先生和罗开瑞先 生计划在本公告披露之日起 15 个交易日后的 3 个月内以集中竞价方式、大宗交 易的方式减持其持有的公司股份不超过 289,200 股（占公司总股本的 0.1165%）、 山西仟源医药集团股份有限公司（以下简称"公司"）于近日收到董事、高 级管理人员俞俊贤先生、高级管理人员顾宝平先生、虞英民先生、贺延捷先生、 罗开瑞先生出具的《关于股份减持计划的告知函》，现将相关情况公告如下： | 一、股东的基本情况 | | --- | | 股东 ...

证券代码：300254 证券简称：仟源医药 公告编号：2025-061 山西仟源医药集团股份有限公司 关于董事、高级管理人员减持股份的预披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山西仟源医药集团股份有限公司（以下简称"公司"）于近日收到董事、高 级管理人员俞俊贤先生、高级管理人员顾宝平先生、虞英民先生、贺延捷先生、 罗开瑞先生出具的《关于股份减持计划的告知函》，现将相关情况公告如下： | 股东姓名 | 任职情况 | 持股数量（股） | 占公司总股本比例（%） | | --- | --- | --- | --- | | 俞俊贤 | 董事、副总裁、 董事会秘书 | 1,336,800 | 0.5383 | | 顾宝平 | 副总裁 | 325,173 | 0.1309 | | 虞英民 | 总工程师 | 325,173 | 0.1309 | | 贺延捷 | 财务总监 | 250,000 | 0.1007 | | 罗开瑞 | 副总裁 | 250,000 | 0.1007 | 一、股东的基本情况 二、本次减持计划的主要内容 1、拟减持原因： 股权激励缴纳税 ...

Group 1 - The company announced that several executives, including the Vice President and other senior management, plan to reduce their holdings in the company within three months after a 15 trading day period from the disclosure date [1] - The total number of shares to be reduced is up to 426,600 shares, which represents 0.1718% of the company's total share capital [1] - Individual reductions include 289,200 shares by Yu Junxian, 43,700 shares by Gu Baoping, 43,700 shares by Yu Yingmin, 25,000 shares by He Yanjie, and 25,000 shares by Luo Kairui, reflecting varying percentages of the total share capital [1]

Market Expansion - As of June 2025, the company's smoking cessation drug, varenicline tartrate tablets, has entered over 100,000 retail stores in the OTC market, with a target of exceeding 140,000 stores by the end of 2025 and 250,000 stores by the end of 2026 [2][3] Market Capacity - The smoking cessation drug market in China has a significant potential, with over 300 million smokers, and the company aims to cover 50 million smokers over the next 10 years [2] User Demographics - The user demographic for varenicline tartrate tablets spans all age groups, with the highest proportion being male smokers in their 30s [3] Cost of Treatment - The estimated cost for each smoker using the varenicline tartrate tablets for a 3-month treatment course is no more than RMB 2,000 [3] Shareholding and Future Plans - The company acknowledges that its major shareholders have a relatively low holding percentage and plans to promote a stock issuance project to specific investors [3]